Turning to Site B

  • Author: Melania Tesio
  • Published: 24 September 2013
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Nature Chemical Biology/Nature Publishing
thumbnail image: Turning to Site B

The development of numerous tumors is driven by the aberrant activation of a trans-membrane protein called smoothened (Smo). The extracellular portion of this molecule contains two important domains. The first one, site A, is targeted by small inhibitors such as the alkaloid cyclopamine. The second one, site B, is the binding site for oxysterols, a family of oxygenated cholesterol derivatives that activate Smo allosterically.


According to Daniel Nedelcu and colleagues, Harvard Medical School, Boston, USA, smoothened inhibition can be achieved not only by targeting site A but also by antagonizing oxysterol's effects. The researchers synthesized 22-azacholesterol (pictured) and demonstrated that this compound competes with oxysterols for binding to Smo at site B. By doing so, 22-azacholesterol blocked Smo activation through an allosteric mechanism.

The use of 22-azacholesterol might, thus, be a novel and effective strategy to target Smo and prevent its aberrant activation during the development of cancer.


Article Views: 2144

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH